Predicting Real-World Functioning in Schizophrenia: The Relative Contributions of Neurocognition, Functional Capacity, and Negative Symptoms

Zixu Yang, Soon Hong Lee, Nur Amirah Abdul Rashid, Yuen Mei See, Justin Dauwels, Bhing‐Leet Tan, Jimmy LeeFrontiers in Psychiatry 2021 · DOI

Abstract

Neurocognition and functional capacity are commonly reported predictors of real-world functioning in schizophrenia. However, the additional impact of negative symptoms, specifically its subdomains, i.e., diminished expression (DE) and avolition-apathy (AA), on real-world functioning remains unclear. The current study assessed 58 individuals with schizophrenia. Neurocognition was assessed with the Brief Assessment of Cognition in Schizophrenia, functional capacity with the UCSD Performance-based Skills Assessment (UPSA-B), and negative symptoms with the Negative Symptom Assessment-16. Real-world functioning was assessed with the Multnomah Community Ability Scale (MCAS) with employment status as an additional objective outcome. Hierarchical regressions and sequential logistic regressions were used to examine the associations between the variables of interest. The results show that global negative symptoms contribute substantial additional variance in predicting MCAS and employment status above and beyond the variance accounted for by neurocognition and functional capacity. In addition, both AA and DE predict the MCAS after controlling for cognition and functional capacity. Only AA accounts for additional variance in employment status beyond that by UPSA-B. In summary, negative symptoms contribute substantial additional variance in predicting both real-world functioning and employment outcomes after accounting for neurocognition and functional capacity. Our findings emphasize both DE and AA as important treatment targets in functional recovery for people with schizophrenia.

Introduction

In schizophrenia research, "functional recovery"—the ability to live independently and maintain employment—is the ultimate clinical goal. Historically, researchers have prioritized neurocognition (thinking skills like memory and attention) and functional capacity (the ability to perform tasks like managing finances in a controlled setting) as the primary predictors of success.

However, the role of negative symptoms—the "absence" of normal functions, such as lack of motivation (avolition) or reduced emotional range (diminished expression)—remains a point of contention. This study investigates whether negative symptoms provide "incremental validity," offering predictive power for a patient's real-world prospects that cognitive tests alone cannot capture.

Methods and Materials

The researchers conducted a clinical study with 58 outpatients in Singapore. The study utilized a battery of gold-standard assessments to evaluate various domains of the illness:

  • Neurocognition: Measured via the Brief Assessment of Cognition in Schizophrenia (BACS).
  • Functional Capacity: Measured via the UCSD Performance-based Skills Assessment-Brief (UPSA-B), which uses props to simulate real-world tasks like paying bills.
  • Negative Symptoms: Evaluated using the Negative Symptom Assessment-16 (NSA-16), specifically looking at two subdomains: Avolition-Apathy (AA) and Diminished Expression (DE).
  • Real-World Functioning: Assessed via the Multnomah Community Ability Scale (MCAS) and objective employment status.
Table 1: Demographic and clinical characteristics of the study participants.

The team employed hierarchical multiple regression to analyze the data. This statistical approach enters variables into the model sequentially (Cognition → Capacity → Negative Symptoms), allowing researchers to isolate the specific amount of new variance each variable adds to the prediction of real-world outcomes.

Key Results

The "Missing Piece" of the Puzzle

Neurocognition and functional capacity initially explained a modest portion of the variance in real-world functioning. However, the inclusion of negative symptoms dramatically improved the model's predictive power. As shown in the hierarchical regression analysis, when negative symptoms were added in Step 3, the explained variance jumped significantly.

Table 2: Hierarchical regression analysis predicting real-world functioning (MCAS) showing the incremental variance provided by negative symptoms.

Specifically, neurocognition alone explained approximately 11-13% of the variance. Adding functional capacity contributed an additional 6%. Crucially, adding negative symptoms contributed a massive 30% increase in explained variance, bringing the total to 46%. This suggests that negative symptoms are a primary driver of disability rather than a mere byproduct of cognitive decline.

Avolition as the Employment Gatekeeper

While both apathy (AA) and lack of expression (DE) predicted general community functioning (MCAS), only Avolition-Apathy was a significant predictor of objective employment status. Sequential logistic regression showed that while functional capacity initially predicted employment ($p = 0.025$), its significance vanished once negative symptoms were added. Only the AA subdomain remained a significant predictor of having a job ($p = 0.032$). This indicates that even if a patient possesses the necessary skills (capacity), a lack of motivation (avolition) remains a critical barrier to securing employment.

Discussion and Future Directions

These findings suggest that in real-world settings, a patient's drive and social presence may outweigh their raw scores on cognitive tests. Interestingly, once negative symptoms were factored in, neurocognition and functional capacity became non-significant predictors in the final model.

Limitations

  • Sample Size: The study's small sample (N=58) may limit generalizability.
  • Scope of Symptoms: The NSA-16 scale does not fully capture "anhedonia" (the inability to feel pleasure), a core negative symptom.
  • Causality: As a cross-sectional study, it identifies associations rather than definitive causal links.

Clinical Implications

The study advocates for a shift in clinical focus. While "brain training" (cognitive remediation) remains valuable, there is an urgent need for psychosocial interventions that specifically target motivation and social engagement to improve functional recovery and employment rates in individuals with schizophrenia.

Summary updated

Abstract

Neurocognition and functional capacity are commonly reported predictors of real-world functioning in schizophrenia. However, the additional impact of negative symptoms, specifically its subdomains, i.e., diminished expression (DE) and avolition-apathy (AA), on real-world functioning remains unclear. The current study assessed 58 individuals with schizophrenia. Neurocognition was assessed with the Brief Assessment of Cognition in Schizophrenia, functional capacity with the UCSD Performance-based Skills Assessment (UPSA-B), and negative symptoms with the Negative Symptom Assessment-16. Real-world functioning was assessed with the Multnomah Community Ability Scale (MCAS) with employment status as an additional objective outcome. Hierarchical regressions and sequential logistic regressions were used to examine the associations between the variables of interest. The results show that global negative symptoms contribute substantial additional variance in predicting MCAS and employment status above and beyond the variance accounted for by neurocognition and functional capacity. In addition, both AA and DE predict the MCAS after controlling for cognition and functional capacity. Only AA accounts for additional variance in employment status beyond that by UPSA-B. In summary, negative symptoms contribute substantial additional variance in predicting both real-world functioning and employment outcomes after accounting for neurocognition and functional capacity. Our findings emphasize both DE and AA as important treatment targets in functional recovery for people with schizophrenia.
BibTeX
@inproceedings{yang2021predicting,
  author = {Zixu Yang and Soon Hong Lee and Nur Amirah Abdul Rashid and Yuen Mei See and Justin Dauwels and Bhing‐Leet Tan and Jimmy Lee},
  title = {{Predicting Real-World Functioning in Schizophrenia: The Relative Contributions of Neurocognition, Functional Capacity, and Negative Symptoms}},
  booktitle = {Frontiers in Psychiatry},
  year = {2021},
  doi = {10.3389/fpsyt.2021.639536},
}
Figure